Evidence map›Paper›PMID 41278442›Full record

ReviewWorld journal of diabetes2025

Pharmacological management of major complications following left ventricular assist device implantation in type 2 diabetes mellitus.

Ying-Lu Zhang, Wen-Yan Wang, Zhen-Yu Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ying-Lu ZhangDepartment of Cardiology, Institute of Cardiovascular Diseases, Heart Failure Center, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Wen-Yan WangDepartment of Cardiology, Institute of Cardiovascular Diseases, Heart Failure Center, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Zhen-Yu LiuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. liuzhenyu200210@sjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Left ventricular assist devices (LVADs) represent a cornerstone therapy for advanced heart failure. However, their efficacy in patients with type 2 diabetes mellitus (T2DM) is challenged by diabetes-exacerbated complications. To determine optimal pharmacological strategies to mitigate major LVAD-related complications in patients with T2DM. This review provides evidence for pharmacological strategies to mitigate major LVAD-related complications in T2DM, in which endothelial dysfunction (

Indexed as

BleedingHeart failureLeft ventricular assist devicesPharmacological managementType 2 diabetes mellitus

Identifiers

PMID41278442
PMCPMC12635750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.